

PROLIGHT ANNOUNCES ADDITIONAL SUBSCRIPTION COMMITMENTS FROM THE BOARD, MANAGEMENT AND EXISTING SHAREHOLDERS

Prolight Diagnostics ("Prolight" or the "Company") is pleased to announce that additional subscription commitments have been received from the Company's board of directors and management in the ongoing rights issue of shares that Prolight resolved on, following approval from the subsequent extraordinary general meeting, on May 21, 2025 (the "Rights Issue"). The Company's nominated Chairman of the Board, Fredrik Alpsten, has undertaken to subscribe for shares of SEK 3 million, the Company's Board member Kiarash Farr has committed to subscribe for an additional SEK 1 million and Board member and CEO Ulf Bladin has committed to subscribe for an additional SEK 1 million.

In addition to the subscription commitment from Fredrik Alpsten and additional subscription commitments from Kiarash Farr and Ulf Bladin totaling SEK 5 million, Prolight has received additional subscription commitments and subscription intentions from existing shareholders of approximately SEK 2.1 million. In total, the Rights Issue is thus covered by subscription commitments and subscription intentions of approximately SEK 23.3 million, corresponding to 23.2 per cent of the Rights Issue.

Nominated Chairman of the Board, Fredrik Alpsten, comments:

"During my years in the life sciences sector, I have witnessed the significant and rapidly growing need for point-of-care solutions. Prolight's point-of-care system has an incredibly important role to play in contributing to fast and accurate diagnoses. The results obtained last week from fresh whole blood samples taken from cardiac patients at St Thomas' Hospital were highly significant. They also confirmed Prolight's previous positive preclinical validation study using biobank plasma samples. It is therefore only natural for me to be committed to the company not only as a board member, but also as a major shareholder."

Subscription commitments and subscription intentions

In addition to previously communicated subscription commitments, the Company can now announce that the Company's nominated Chairman of the Board Fredrik Alpsten has committed to subscribe for shares with and without preferential rights of SEK 3 million in the Rights Issue. Fredrik is nominated to be elected and take office at the Annual General Meeting to be held on June 30, 2025. In addition to Fredrik, the Company's CEO and Board member Ulf Bladin has also committed to subscribe for shares for an additional SEK 1 million, corresponding to a total commitment of SEK 2 million. In addition to Ulf and Fredrik, Board member Kiarash Farr has also committed to subscribe for shares for an additional SEK 1 million, corresponding to a total commitment of SEK 1.5 million.

In addition to the above and previously communicated commitments, the Company has received additional subscription commitments and subscription intentions from existing shareholders of approximately SEK 2.1 million. The Rights Issue is covered by subscription commitments of approximately SEK 21.7 million, corresponding to approximately 21.6 percent of the Rights Issue, and subscription intentions of approximately SEK 1.6 million, corresponding to approximately 1.6 percent of the Rights Issue. In total, the Rights Issue is thus covered by subscription commitments and subscription intentions of approximately SEK 23.3 million, corresponding to 23.2 percent of the Rights Issue.

No compensation will be paid for the submitted subscription commitments. The commitments are not secured pledged assets, restricted funds or similar arrangements. Subscription intentions are not a written commitment.

Indicative timetable

June 16 – June 25, 2025	Trading in subscription rights (TR) on NGM
June 16 – June 30, 2025	Subscription period in the Rights Issue
June 16 – July 16, 2025	Expected trading in paid subscribed shares (BTA) on NGM
July 2, 2025	Estimated date for announcement of issue outcome

Advisors

Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight announces additional subscription commitments from the board, management and existing shareholders